Pharming Group NV
Research Pharming Group NV (PHARM) on Bullrun: valuation model: 30.0% overvalued, market cap EUR 829.85M, P/E 83.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHARM
- ExchangeAS
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Valuation signal30.0% overvalued
- Market capEUR 829.85M
- P/E83.0
- Financial periodFY2025
- RevenueUSD 376.13M
- Revenue growth26.6%
- Net incomeUSD 2.54M
- Free cash flowUSD 53.96M
- Gross margin87.9%
Valuation Snapshot
Bullrun's latest valuation model marks Pharming Group NV as 30.0% overvalued; latest market cap is EUR 829.85M; P/E is 83.0.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE);
Frequently asked questions
Is Pharming Group NV overvalued or undervalued?
Bullrun's valuation model currently marks Pharming Group NV as 30.0% overvalued.
What is Pharming Group NV's market cap?
Pharming Group NV's market capitalization is EUR 829.85M.
What is Pharming Group NV's P/E ratio?
Pharming Group NV's price-to-earnings (P/E) ratio is 83.0.
What does Pharming Group NV do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.